Navigation Links
ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
Date:9/6/2007

SEATTLE, Sept. 6 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (Nasdaq: ZGEN) announced today that Douglas E. Williams, Ph.D., President and Chief Scientific Officer, will provide an overview of company activities at the Bear Stearns Annual Healthcare Conference on September 10, 2007 at 8:00 a.m. Eastern Time and at the UBS Global Life Sciences Conference on September 24, 2007 at 12:30 p.m. Eastern Time.

Live webcasts of both presentations can be accessed by going to: http://www.zymogenetics.com. The webcasts will be archived for 30 days.

About ZymoGenetics

ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of proprietary product candidates that are moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune and viral diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit http://www.zymogenetics.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. ZymoGenetics' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, preclinical and clinical development, regulatory oversight, intellectual p
'/>"/>

SOURCE ZymoGenetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sonic Foundry to Webcast Bridge Arch Floating Down Mississippi
2. New Sonic Foundry search engine finds words, phrases in video presentations
3. Sonic Foundry creates search engine for 7,000 expert video presentations
4. InvestMidWest calls for business presentations
5. BxVideo designs Web hosting service for Sonic Foundry media presentations
6. Distance Education Conference Selects Sonic Foundry to Make Keynotes, Panel Presentations Available On-Demand
7. Merge announces sofware updates, upcoming acquisition
8. Can tech people be business leaders? Upcoming seminar may have the answer
9. State of biotech, medical device sector is focus of upcoming conference
10. Telecom issues are among focus of upcoming western Wisconsin conference
11. Upcoming technology conferences look at government tech and RFID issues

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... Intarcia Therapeutics, Inc. deliv...S® continuous delivery of exenatide) program ...Annual Diabetes Technology Meeting in San Francisc...n/prnh/20050301/SFTU126LOGO ) ,, Continuous S...ers Plasma Glucose, HbA1c and Reduces Weight in a ...
(Date:11/5/2009)... 5 GenVec, Inc. (Nasdaq:... the third quarter ended September 30, 2009. GenVe...hare) for the three months ended September 30, 200...r share) in the comparable quarter of 2008. For th...et loss was $14.1 million ($0.15 per share), compa...
(Date:11/5/2009)...wswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulleti...er, President and CEO of Imagenetix, will be prese...RO Conference on Thursday, December 3rd, at 10:30 ...out LD MICRO ,, LD MICRO is a by-invitation onl...ued companies in the micro-cap space. Since 2002, ...
(Date:11/5/2009)...Newswire-FirstCall/ -- Transgenomic, Inc. (OTC Bul...ts for the quarter ended September 30, 2009. The C...bles that follow. ,, Third Quarter 2009 ,,....01 per share for the third quarter of 2009 as com... for the third quarter of 2008. ,, Net sales w...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...harmaceuticals,a division of Wyeth (NYSE: WYE ), ...ments with Solvay Pharmaceuticals for the developm... other compounds in earlier,stages of development ...ther psychiatric conditions., Wyeth terminated th...portunity for bifeprunox and determining it would ...
...ng distributor of market,intelligence, MarketResea...hip with Spectra Intelligence which allows for the...ry market analyses through the,MarketResearch.com ...ofessionals throughout the world,easy access to co... from,research publications authored by market exp...
...ex, Inc.,(Nasdaq: MEDX ) announced today that it ...al Group Second Annual SIGnificant Investment Opti...dnesday, March 5, 2008, in New,York. The event wil...estor,Relations section of the Medarex website at ...he presentation will be available following the ev...
Other Biology Technology:Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds 2MarketResearch.com Announces Distribution of Spectra Intelligence Research 2Medarex to Present at the Susquehanna Financial Group Healthcare Conference 2
(Date:11/5/2009)...ssociation of Biology Teachers (NABT) will recogni...ciences at Naugatuck Valley Community College (NVC...ion Education Award during the NABT annual profess...mber 2009 in Denver, Colorado. , The Evolution E...itute of Biological Sciences,(AIBS) and Biologica...
(Date:11/5/2009)...versity has been awarded a training grant in the a...tion under its Integrative Graduation Education an...irst IGERT grant to be awarded to Kent State. The ... and Reinvestment Act of 2009, runs through 2014. ...on environment aquatic resource sensing (EARS). Th...
(Date:11/4/2009)... news in natural science) , United States Usin...s water today than it did 35 years ago, despite a ...use are partly attributable to alternative cooling...tion systems. According to the latest USGS water u...ited States goes to cooling thermoelectric power p...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Roux en Y weight loss surgery raises kidney stone risk 49271 1Roux en Y weight loss surgery raises kidney stone risk 49271 2Valensa Selects Parry Organic Spirulina as Ingredient of Choice for Premium Product Development 49269 1Valensa Selects Parry Organic Spirulina as Ingredient of Choice for Premium Product Development 49269 2Valensa Selects Parry Organic Spirulina as Ingredient of Choice for Premium Product Development 49269 3Valensa Selects Parry Organic Spirulina as Ingredient of Choice for Premium Product Development 49269 4Taking Aim at Relapse of Leukemia in Kids 49267 1Taking Aim at Relapse of Leukemia in Kids 49267 2
...r deterioration seen in muscular dystrophy can be ...y for their effects against cancer, a Burnham Inst... the potential use of these drugs, called histone ...and repair of dystrophic muscles, thereby counteri...t mouse models of muscular dystrophy. Led by Burnh...
...new project being developed by Central Queensland ... surgery patients around the country could soon ha...t of their own home rather than having to travel t... University’s Rockhampton campus are developing an...ple who have had heart surgery to see if it improv...
...technical advance in the study of the complex rece...researchers at the University of California, San D...the signaling pathways that impact activation of a...ing and to the thrombosis that occurs in heart att...re-build the signaling pathway that regulates acti...
Other Biology News:Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy 2UCSD researchers create roadmap to integrin activation 2UCSD researchers create roadmap to integrin activation 3
BMP-2 ELISA Kit from R&D Systems
5x MONO-RABBIT POLY C'GATE DILUENT from AbD Serotec
Argarase from BioVision
SAMPLE DILUENTS BUFFER TRIAL PACK from AbD Serotec
Biology Products: